Advertisement
Australia markets closed
  • ALL ORDS

    8,022.90
    -54.00 (-0.67%)
     
  • AUD/USD

    0.6682
    +0.0032 (+0.48%)
     
  • ASX 200

    7,783.00
    -55.80 (-0.71%)
     
  • OIL

    81.37
    +0.54 (+0.67%)
     
  • GOLD

    2,327.10
    -3.70 (-0.16%)
     
  • Bitcoin AUD

    92,146.16
    +694.32 (+0.76%)
     
  • CMC Crypto 200

    1,278.18
    -5.60 (-0.44%)
     

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd.

HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time).

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ®

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com